Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden.
Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, Hildebrandt G, Gergis U, Farhadfar N, Freytes CO, Kamble RT, Krem M, Kyle RA, Lazarus HM, Marks DI, Meehan K, Patel SS, Ramanathan M, Olsson RF, Wagner JL, Kumar S, Qazilbash MH, Shah N, Hari P, D'Souza A.
Cornell RF, et al. Among authors: goodman s.
Transplant Cell Ther. 2021 Mar;27(3):264.e1-264.e7. doi: 10.1016/j.jtct.2020.11.018. Epub 2020 Dec 16.
Transplant Cell Ther. 2021.
PMID: 33781533
Free PMC article.